This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.
” These dense webs of overlapping patent rights can significantly impact innovation, market entry, and competition across various industries and countries. Easier market entry: Less dense thickets may make it easier for new players to enter markets.
Fosun Pharma is granted an exclusive license to develop, manufacture, and commercialize TEV-56278 in Chinese mainland, Hong Kong Special Administrative Region (SAR), Macau SAR, Taiwan, and select Southeast Asian countries. This collaborative framework specifies the respective responsibilities for each party.
Published July 8, 2025 Gwendolyn Wu Senior reporter post share post print email license Proteasomes are cellular machines for breaking down proteins. Drugmakers are working to coopt this process with targeted therapies.
The strategic funding arrangement is designed to support the continued advancement and global commercialization of Revolution Medicines’ RAS(ON) inhibitor portfolio, including its lead candidate daraxonrasib, as the company scales its operations independently across the international oncology market.
He holds a master’s degree from University of Salerno in political sciences and marketing. He also develops and presents customised training programmes (both live and virtual) for companies seeking to improve their in- and out-licensing processes. Connect on LinkedIn >> Alessio Zoccoli applies AI for a sustainable future.
I saw an opportunity which others didn’t, to develop a small molecule targeting a well-known cancer pathway, a master switch of cancer Afterwards, I moved to Germany to work for Merck KGaA, where I headed up the licensing and business development team. I would also advise anyone, young women and men included, to always believe in themselves.
Whether directed to a product of an AI or the AI itself, securing a patent is advantageous because it gives the owner exclusive rights to manufacture, use, sell or license their invention for a specified period. Patents can attract investors by assuring intellectual property protection.
Real technology spend includes observability tools, containers, data platforms, SaaS licensing, AI/ML, and peripheral services, sometimes hand-waved away as shadow IT or just life as part of an unavoidable cost center. Complexity is increasing: multicloud and hybrid environments are the norm.
A well-known example is Merck’s rofecoxib , approved for pain relief in 1999 but withdrawn from the market in 2004 due to cardiovascular risks that were not sufficiently monitored during post-market surveillance. This means pharmaceutical companies must remain vigilant and adaptable to comply with evolving regulations.
Published July 14, 2025 Ben Fidler Senior Editor post share post print email license Takeda reported positive results for oveporexton, a drug being developed for narcolepsy Type 1, on July 14, 2025. The drug, formerly known as TAK-861 but now called oveporexton, was evaluated in two Phase 3 studies in a main type of narcolepsy.
Global Licensing and Commercialization Agreement MR-141 is being developed under a global licensing agreement between Viatris and Opus Genetics. Further details on the VEGA-3 trial, including inclusion criteria and study design, are publicly available on ClinicalTrials.gov under the identifier NCT06542497.
under license from Zymeworks Inc. , EU, Japan, and most global markets outside of the Asia-Pacific region (excluding Japan), which remain under BeiGene’s purview. Ziihera is being jointly developed by Jazz Pharmaceuticals and BeOne Medicines Ltd. formerly BeiGene, Ltd.) the original developer. In the U.S.,
The antibiotic market has long faced significant barriers to innovation, with structural issues that make it difficult for new antibiotics to gain traction. As the demand for novel antibiotics remains limited due to the preference for cheaper generics, the market has struggled to incentivise much-needed breakthroughs.
This aligns both parties’ interests toward long-term success in the market. The synthetic royalty component involves payments to Royalty Pharma based on future net product sales of daraxonrasib, once approved and commercialized. In addition to the royalty, Royalty Pharma will provide a senior secured loan facility of up to $750 million.
This expanded partnership reflects Bayer’s ongoing commitment to strengthening its presence in China—home to the world’s second-largest pharmaceutical market—and underscores its strategic vision to bolster healthcare innovation through cross-sector collaboration.
2] Gepirone was synthesized by Bristol-Myers Squibb in 1986 and was developed and marketed by Fabre-Kramer Pharmaceuticals. [4] 5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. 1] It is taken orally. [1] 1] It is taken orally. [1]
11] [21] [22] In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Agamree, intended for the treatment of Duchenne muscular dystrophy. [2] 2] [3] Brand names Vamorolone is the international nonproprietary name. [23]
From mergers and acquisitions to licensing agreements and pricing discussions, these complex interactions demand a unique blend of scientific knowledge, business acumen, and interpersonal skills. Intellectual property is often a central issue in pharmaceutical negotiations, particularly in licensing deals and partnerships.
Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer. In a research note on Wednesday, RBC Capital Markets analyst Leonid Timashev estimated peak yearly sales of the drug could reach nearly $640 million.
Kyle notes that “clinical trials face costly delays, inefficient resource allocation, and even standstill or stalling of trials, ultimately resulting in the failure to bring crucial treatments to market.” Jennifer has been a licensed CPA (California) since July 2014. Available from: [link]
Of course the larger markets would be in non-NRG1 fusion cancers where HER3 is overrexpressed but Partner Therapeutics does not appear to be supporting additional clinical trials. On this basis, and to drive use of the RNA sequencing technology that identifies NRG1 fusions, the drug was purchased by Partner Therapeutics.
Most Popular 5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis Dispatch emerges with $216M and plans for a ‘universal’ solid tumor therapy FDA delays approval decision for Bayer menopause therapy Biotech startup funding dried up in second quarter, HSBC finds Library resources Infographic Tech Transfers: 5 CDMO Strategies to Speed Time (..)
Published June 26, 2025 Gwendolyn Wu Senior reporter post share post print email license B cells, like those pictured above, malfunction in autoimmune disease. Vor Biopharma licensed a drug in June 2025 that targets proteins essential to B cell survival. and European drugmakers.
Published July 10, 2025 Delilah Alvarado Staff Reporter post share post print email license The Food and Drug Administration on July 10, 2025, issued Moderna a full approval in children for its COVID-19 vaccine Spikevax. Kennedy Jr., who has pushed for policy changes around mRNA vaccines in particular.
Published July 10, 2025 Ben Fidler Senior Editor post share post print email license Soleno Therapeutics on July 10, 2025 announced preliminary sales for its new Prader-Willi Syndrome drug Vykat. Until Vykat came along, though, no drug therapies were specifically approved to curb the all-consuming hunger that hallmarks the condition.
Published July 18, 2025 • Updated 3 hours ago Ned Pagliarulo Lead Editor post share post print email license The U.S. Alamy The Food and Drug Administration will ask Sarepta Therapeutics to halt all shipments of its marketed gene therapy for Duchenne muscular dystrophy, a source familiar with the matter confirmed to BioPharma Dive.
A key enzyme in B cell stimulation and survival is BTK, and pirtobrutinib inhibits BTK in a way that is different from the prototypical BTK inhibitor ibrutinib by binding in a different way that avoids a genetic change (mutation at active site cysteine residue C481 in BTK) that can make some tumors less responsive to ibrutinib. [5] 27 January 2023.
gmol 1 3D model ( JSmol ) Interactive image show SMILES show InChI Prete A, Auchus RJ, Ross RJ: Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia.
For years, the company was primarily known for licensing its C1 platform for the development of therapeutic biologics and vaccines. Unlike therapeutic biologics, non-therapeutic proteins face fewer regulatory hurdles, significantly lower development costs, and faster time-to-market.
Published July 2, 2025 By Kristin Jensen post share post print email license Endometriosis involves the outgrowth of womb lining tissue in the pelvis or abdomen. Organon acquired the drug in its purchase of Forendo Pharma in 2021. But many development hurdles still stand in the way of new medicines for the brain.
Published June 26, 2025 Ned Pagliarulo Lead Editor post share post print email license An Incyte researcher works in a laboratory. and sold [Karuna],” wrote RBC Capital Markets analyst Brian Abrahams, in a note to clients. On June 26, 2025, the company announced the replacement of longtime CEO Hervé Hoppenot with Bill Meury.
As a business professional in the pharmaceutical industry, understanding and implementing effective strategies for drug patent prosecution can be the difference between market domination and missed opportunities. However, because it takes so long to bring a drug to market, the effective patent life is often much shorter.
Published June 27, 2025 Ned Pagliarulo Lead Editor post share post print email license Bristol Myers Squibb sells two CAR-T cell therapies for cancer. Dive Insight: Since the FDA’s approval of Novartis’ Kymriah for leukemia in 2017, six more CAR-T therapies have reached market.
This comprehensive guide will walk you through the intricacies of optimizing your drug patent strategy, ensuring that your innovations are safeguarded and your market position is strengthened. Licensing and Partnerships A strong patent portfolio can open doors to lucrative licensing agreements and strategic partnerships.
Fragmented approaches – whether through retail or oversized specialty hub models, or limited alternative solutions that lack true integration – simply cannot deliver the efficiency, control, and customization that market-defining brands need. Book a demo to discover how PHIL can help your specialty-lite brands secure commercial success.
But Sensei’s true value isnt limited to content operations, it’s the unified AI engine that quietly powers marketing intelligence, customer personalization, and even creative automation across Adobes enterprise ecosystem. This post takes a broader look at how Adobe Sensei connects data, creativity, and experiences, at scale.
Under Birgitte’s guidance, Genmab successfully navigated key licensing agreements, multiple strategic collaborations with leading pharmaceutical companies, and its listing on the Nasdaq Global Select Market.
Comprehensive Report Reveals Key Trends in Gynecology Collaboration and Licensing Deals from 2016 to 2025 Gynecology Collaboration and Licensing Deals report offers a deep dive into the evolving landscape of partnerships in women’s health, providing unparalleled insights into over 150 strategic deals executed globally between 2016 and 2025.
We also offer licenses to our secure hosted learning environmentno internal setup required! Sorry, individual licenses are not currently available.) What Youll Learn: A Snapshot of Each Module 1.
"Unlocking the Secrets to Smarter Partnerships: How One Tool is Revolutionizing the Way Pharma Companies Approach Out-Licensing and Partnering Decisions As the pharmaceutical industry continues to evolve, companies are under increasing pressure to maximize their portfolios and minimize risk.
Some on Wall Street believe the New York-based biotechnology company is now less likely to get acquired after agreeing to sell partial rights to its only marketed product.
The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.
The biological license application (BLA) is one of the many requests for marketing approval received by the FDA. Unlike the New Drug Application (NDA) which is usually the go-to submission for chemically synthesized, low molecular weight drugs BLAs grant sponsors the ability to introduce Biologics into interstate commerce.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content